Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/34872
Title: Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso
Authors: Innocent Valea
Halidou Tinto
Maminata Traore Coulibaly
Laeticia C. Toe
Niklas Lindegardh
Joel Tarning
Jean Pierre Van Geertruyden
Umberto D'Alessandro
Geraint R. Davies
Stephen A. Ward
Centre MURAZ
Unité de Recherche Clinique de Nanoro
Institut de Recherche en Sciences de la Santé
Mahidol University
Nuffield Department of Clinical Medicine
Universiteit Antwerpen
Prins Leopold Instituut voor Tropische Geneeskunde
Medical Research Council Unit
University of Liverpool
Liverpool School of Tropical Medicine
Keywords: Medicine;Pharmacology, Toxicology and Pharmaceutics
Issue Date: 1-Jan-2014
Citation: Journal of Antimicrobial Chemotherapy. Vol.69, No.9 (2014), 2499-2507
Abstract: Objectives: Mefloquine/artesunate has recently been developed as a fixed-dose combination, providing a promising rescue/alternative treatment for malaria during pregnancy. However, limited data are available on the effect of pregnancy on its pharmacokinetic properties. This study was conducted to assess the pharmacokinetic properties of mefloquine/carboxymefloquine and artesunate/dihydroartemisinin in pregnant and non-pregnant women with uncomplicated malaria. Methods: Twenty-four women in their second and third trimesters of pregnancy and 24 paired non-pregnant women were enrolled. All patients were treated for uncomplicated Plasmodium falciparum malaria with a standard fixed-dose combination of oral mefloquine and artesunate one daily over 3 days. Frequent blood samples were collected before treatment and at scheduled times post-dose for the drug measurements and pharmacokinetic analyses. The study was registered at www.clinicaltrials.gov (identifier: NCT00701961). Results: The total median exposure to mefloquine and dihydroartemisinin was not significantly different between the pregnant and non-pregnant women (P>0.05). Therewas a trend of higher exposure tomefloquine in the pregnant women, but this difference did not reach statistical significance (656700 versus 542400 h×ng/mL; P=0.059). However, the total exposure to carboxymefloquine was 49% lower during pregnancy (735600 versus 1499000 h×ng/mL; P<0.001) and the total drug exposure to artesunate was 42% higher during pregnancy (89.0 versus 62.9 h×ng/mL; P=0.039) compared with non-pregnant controls. Conclusions: The plasma levels ofmefloquine and dihydroartemisinin appeared to be similar in both pregnant and non-pregnant women, but there were significant differences in carboxymefloquine and artesunate exposure. The data presented here do not warrant a dose adjustment in pregnant patients, but an extensive analysis of the data could provide a better understanding of these findings. © The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84905987915&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/34872
ISSN: 14602091
03057453
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.